Bone marrow transplant recipients may be at increased risk of osteoporosis. In a cross-sectional study we therefore measured two biochemical markers of bone turnover, bone alkaline phosphatase and the C-terminal propeptide of type I procollagen, in 22 serum samples from 9 patients before ailogeneic bone marrow transplantation and 85 serum samples from 14 patients after ailogeneic bone marrow transplantation.
Introduction
Osteoporosis is a complication for which bone marrow transplant recipients may be at increased risk [for review see I.e. (1)]:
(a) cyclosporin A therapy in immunosuppressive doses can induce osteopenia; (b) glucocorticoids predispose to osteopenia by depressing bone formation and increasing bone resorption; (c) sex hormone deficiency increases bone loss, especially in women following pretransplant conditioning with total body irradiation and chemotherapy.
Reduced bone mineral density in patients following bone marrow transplantation has already been shown (2) . Bone alkaline phosphatase (EC 3.L3.1) is an enzyme localized in the plasma membrane of osteoblastic cells (3) . Type I collagen is the sole collagen type found in bones. The carboxy-terminal propeptide of procollagen type I is cleaved during extracellular processing of bone procollagen and appears in the blood (4) . Both analytes may be considered as markers of bone turnover. In the present cross-seetional study we report on the diagnostic validity of these biochemical markers in the follow-up of bone metabolism in patients receiving ailogeneic bone marrow transplantation.
Patients and Methods

Patients
We examined (a) 22 serum samples from 9 patients before ailogeneic bone marrow transplantation (age: 35 ± 2.2 years) (mean ± SEM) (5 males, 4 females) (4 chronic granulocyte leukaemia, 3 acute non-lymphoblastic leukaemia, 2 'high-grade' non-Hodgkin's lymphoma) and (b) 85 serum samples from 14 patients after ailogeneic bone marrow transplantation (age: 37 ± 2.3 years) (mean ± SEM) (10 males, 4 females) (7 chronic granulocyte leukaemia, 4 acute nonlymphoblastic leukaemia, I acute lymphoblastic leukaemia, 2 'high-grade 1 non-//odg/urVs lymphoma).
The mean time since transplantation was 335 ± 82 (mean ± SEM) days. The subjects received pretransplant conditioning with total body irradiation (10 Gy) and 'high-dose' cyclophosphamide (120 mg/kg). For prevention of graft-versus-host disease all patients received cyclosporin A (4 mg/kg · d i. v. then 12 mg/kg · d p.o.) for 216 ±45 (mean ± SEM) days and 'short-term* methotrexate (15 mg/m 2 body surface at day 1 and 10 mg/m 2 body surface at days 3 and 6 after bone marrow transplantation). None of the patients received corticosteroids. Moreover, none of the female patients were receiving oestrogen therapy at the time of the study. All female patients following bone marrow transplantation had clinical and biochemical evidence of primary ovarian failure. The number of serum samples obtained from each patient ranged from 2 to 14 (mean: 5). None of the patients had any previous history of bone disease. Since this was a cross-sectional study, the patients examined before bone marrow transplantation were different from those examined after transplantation.
Determination of serum analytes
Bone alkaline phosphatase mass concentration in serum was determined by an immunoradiometric assay (Tandem®-R Ostase™; Hybritech Inc., San Diego, CA [U. S. A.]; no. 3040 BE) employing two monoclonal antibodies against two different epitopes of the bone alkaline phosphatase molecule. A calibration curve was constructed by linear interpolation between the plotted analytical results. The following reference intervals (2.5th-97.5th percentile) for bone alkaline phosphatase concentration in serum were established in apparently healthy persons: (1) 3.8-21.3 μg/l (males, n = 51) (2) 3.4-15.0 pg/1 (females, n = 51); age range 20-55 years (males) and 18-56 years (females).
The concentration of the carboxy-terminal extension peptide of procollagen type I in serum was determined by an enzyme immunoassay (Prolagen-C™; Metra Biosystems, Inc., Palo Alto, CA [U. S. A.]). A calibration curve was constructed by a 4-parameter curve fitting 'algorithm. The following reference intervals (2.5th-97.5th percentile) for the C-terminal propeptide in serum were established in apparently healthy persons: (1) 50-180 μg/l (males, n = 51) (2) 50-145 μg/l (females, n = 51); age range 23-58 years (males) and 23-59 years (females).
The urinary excretion of "pyridinium cross-links" of collagen was determined by a competitive enzyme immunoassay (Collagen Crosslinks™ Kit; Metra Biosystems Inc.; Palo Alto, CA [U. S. A.]) employing a polyclonal antibody against pyridinoline which shows 100% cross-reactivity with deoxypyridinoline. A curve was constructed employing a 4-parameter curve fitting equation. The following reference interval (mean ± 2 X SD) for the urinary excretion of pyridinium cross-links in 'second morning' urine samples was established in 40 apparently healthy female persons (agerange: 20-56 years) (the samples were obtained between 8.00 and 10.00 a.m.): pyridinoline equivalents, 13-73 μπιοΐ/mol creatinine. The age distribution of these reference individuals did not significantly differ from that of the female patients examined (see above) (p > 0.05).
Total alkaline phosphatase activity in serum was measured at + 25 °C by the optimized standard method conforming to the Recommendations of the German Society for Clinical Chemistry (5) using the fully mechanized analyser Hitachi/BM 737 (Boehringer Mannheim GmbH, Mannheim, Germany) (reference range: 78-178 U/l [males] and 59-160 U/l [females]).
Serum γ-glutamyl transferase activity was measured at + 25 °C according to Szasz (6) using the fully mechanized analyser Hitachi/ BM 737 (Boehringer Mannheim GmbH, Mannheim, Germany) (reference range: 6-28 U/l [males] and 4-18 U/l [females]).
Statistical analysis
As statistical methods we used the U-test according to Wilcoxon, Mann & Whitney (two-tailed) for unpaired samples, linear regression equations, and linear correlation coefficients (7).
Multiple regression analysis was performed with the help of SPSS/ PC+™ V2.0 employing the procedure REGRESSION with a 'stepwise' selection of the independent variables. An association between the values of the bone metabolism markers and liver dysfunction (as assessed by γ-glutamyl transferase activities) was examined by analysis of variance employing the procedure 'ANOVA' (SPSS/PC+™ V2.0).
All values are given as mean ± SEM.
Results
Values of bone turnover markers before and after allogeneic bone marrow transplantation
Comparison of the mean values from each patient showed that the serum bone alkaline phosphatase values of female patients were higher after than before allogeneic bone marrow transplantation: 14.4 ± 2.0 μg/l (after) vs 7.3 ± 1.0 μ^ (before) (p < 0.05). This did not apply to male patients: 13.1 ± 1.9 ngfl (after) vs 13.1 ± 1.8 (before) (p < 0.5).
To assess whether the increased values of serum bone alkaline phosphatase actually reflect increased bone turnover, we determined the "pyridinium cross-links" of collagen in 'second morning' urine samples (collected between 8.00 and 10.00 a.m.) corresponding to those sera obtained from female patients following bone marrow transplantation. There was a significant increase in the urinary excretion of this bone resorption marker (56 ± 9 μιηοΐ/mol creatinine) as compared to an ageand sex-adjusted control collective (see Materials and Methods) (p < 0.05).
The values of serum total alkaline phosphatase activity showed the same behaviour except that the increase in total alkaline phosphatase activity (as found in female patients) did not attain the significance level: 143 ± 34 U/l (after) vs 85 ± 5 U/l (before) (p = 0.083) [females] and 143 ± 18 U/l (after) vs 124 ± 17 U/l (before) (p > 0.5) [males].
After bone marrow transplantation both female and male patients had higher concentrations of the C-terminal propeptide in their serum: 118 ± 9 μg/l (after) vs 65 ± 5 μg/l (before) (p < 0.01). There was a concomitant increase of serum γ-glutamyl transferase activity following bone marrow transplantation (33 ± 7 U/l [after] vs 14 ± 3 U/l [before]) (p < 0.01).
Relationship between total alkaline phosphatase activities, bone alkaline phosphatase concentrations and C-terminal propeptide levels there was a relationship between bone alkaline phosphatase serum concentrations and total alkaline phosphatase activities/C-terminal propeptide ' serum values (p < 0.0001) ( fig. 1) 
Relative effects of various influences on the values of bone turnover markers
Both before and after bone marrow transplantation there was no significant association between total alkaline phosphatase activities, bone alkaline phosphatase concentrations and C-terminal propeptide values on the one hand, and γ-glutamyl transferase activities (increased or not increased above the upper reference limit) on the other (p > 0.5).
The values of both bone formation markers were increased within the first year after bone marrow transplantation (p < 0.0001) in all the 85 sera examined following allogeneic bone marrow transplantation. Subsequently the serum concentrations of bone alkaline phosphatase significantly decreased (p < 0.01), whereas the decrease of the C-terminal propeptide values in serum did not attain significance level (p = 0.307) (fig. 2) .
The relative effects of various influences on the values of the bone formation markers within the first year after allogeneic bone marrow transplantation were analysed individually and by multiple regression analysis. The independent variables included were creatinine concentration in serum, serum γ-glutamyl transferase activity, duration of cyclosporin A therapy, time since transplantation, age of patients and whether the subjects suffered from chronic graft-versus-host disease or not. Both duration of cyclosporin A therapy (p < 0.05) and time since transplantation (p < 0.01) were independent predictors of serurn bone alkaline phosphatase values, whereas the duration of cyclosporin A therapy was the only independent predictor of C-terminal propeptide serum concentrations (p < 0.01).
Discussion
In females but not in males there was a significant difference between serum bone alkaline phosphatase values before and after allogeneic bone marrow transplantation. This may be explained by the influence of primary ovarian failure following total body irradiation, whereas in men only a moderate elevation of gonadotropins as well as testosterone levels within the reference interval were observed (2, 8) . Cyclosporin A may enhance the deleterious effect of oestrogen deficiency, since in oophorectomized rats bone mass loss is accelerated by the application of cyclosporin A (9).
Cyclosporin A is known to produce high bone remodelling with bone resorption exceeding bone formation after daily oral cyclosporin doses between 7.5 and 15 mg/kg body weight in rats (10, 11) ; this essentially corresponds to the oral dose given to our patients. In patients under immunosuppressive therapy with cyclosporin A a comparable increase of serum (bone) alkaline phosphatase activities was observed after renal transplantation (12) (13) (14) .
Carlson et al. (15) found a depression of bone formation within the first three months following bone marrow transplantation which is probably due to (a) an inhibitory effect of glucocorticoids upon bone formation, (a) The follow-up period of Carlson's study was only 3 months following bone marrow transplantation whereas in the present communication the mean time since transplantation was 335 days. The suppressive effect on osteoblast function reported (15) was only transient, and normal values of bone alkaline phosphatase were regained after 3 months; alterations of cytokine secretion are most strongly pronounced immediately after bone marrow transplantation. In contrast, in patients receiving renal transplants, an activating effect of cyclosporin A upon osteoblast activity (detected by determination of bone turnover markers) can be found 3 months at the earliest after transplantation (12) . Due to the cross-sectional character of our study and the much longer follow-up period we were therefore not able to detect the slight suppressive effects on bone formation shown by Carlson et al. (15) .
(b) No glucocorticoids were given to our patients.
Reduced bone mineral density is a common finding in patients following liver, cardiac and bone marrow transplantation (2, 16-18). Kelly et al. (2) showed that in patients following bone marrow transplantation there is no relationship between bone mineral density and dura- tion of cyclosporin A therapy. This may be due to the fact that some of their patients additionally received glucocorticosteroids.
It has previously been shown in patients with various types of metabolic bone diseases that the serum concentrations of the C-terminal propeptide correlate with histomorphometric variables of bone formation (19) . Corresponding to our findings, a correlation between C-terminal propeptide serum values and serum alkaline phosphatase activities has been observed in cancer patients (20) and in patients with metabolic bone diseases (19) .
In the interpretation of C-terminal propeptide serum concentrations, account must be taken of the fact that a disturbed liver function may result in high serum values, probably due to the involvement of liver endothelial cells in the metabolic clearance of this molecule (19, 21) . Despite the significant increase of serum γ-glutamyl transferase activities following bone marrow transplantation, a major influence of liver function on C-terminal propeptide serum values seems improbable in the present study, because (a) serum γ-glutamyl transferase activity was not an independent predictor of C-terminal propeptide serum values as shown by multiple regression analysis, and (b) 'analysis of variance' revealed no statistically significant association between γ-glutamyl transferase activities and the values of this bone metabolism marker.
It is worth mentioning that bone alkaline phosphatase serum concentrations were increased in 20% of samples with total alkaline phosphatase activities within the reference range, as well as in 18% of samples with Cterminal propeptide serum values within the reference range. This indicates that bone alkaline phosphatase concentrations are more sensitive than the other two measurable quantities in the detection of disturbances of bone metabolism (12) . Therefore in patients following bone marrow transplantation, bone alkaline phosphatase in particular may be a useful marker substance for detection of increased bone turnover.
